- Home
- ATNM vs RAND Comparison
ATNM vs RAND Comparison
Compare ATNM & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNM
- RAND
- Stock Information
- Founded
- ATNM 2000
- RAND 1969
- Country
- ATNM United States
- RAND United States
- Employees
- ATNM N/A
- RAND N/A
- Industry
- ATNM Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- ATNM Health Care
- RAND Finance
- Exchange
- ATNM Nasdaq
- RAND Nasdaq
- Market Cap
- ATNM 56.5M
- RAND 47.5M
- IPO Year
- ATNM N/A
- RAND N/A
- Fundamental
- Price
- ATNM $1.40
- RAND $21.68
- Analyst Decision
- ATNM Strong Buy
- RAND
- Analyst Count
- ATNM 4
- RAND 0
- Target Price
- ATNM $8.75
- RAND N/A
- AVG Volume (30 Days)
- ATNM 342.1K
- RAND 10.4K
- Earning Date
- ATNM 11-14-2024
- RAND 03-04-2025
- Dividend Yield
- ATNM N/A
- RAND 23.20%
- EPS Growth
- ATNM N/A
- RAND 123.39
- EPS
- ATNM N/A
- RAND 4.98
- Revenue
- ATNM $81,000.00
- RAND $8,351,941.00
- Revenue This Year
- ATNM $138.42
- RAND N/A
- Revenue Next Year
- ATNM $19,479.88
- RAND N/A
- P/E Ratio
- ATNM N/A
- RAND $4.35
- Revenue Growth
- ATNM N/A
- RAND 16.96
- 52 Week Low
- ATNM $1.10
- RAND $12.92
- 52 Week High
- ATNM $10.24
- RAND $24.10
- Technical
- Relative Strength Index (RSI)
- ATNM 56.03
- RAND 67.07
- Support Level
- ATNM $1.18
- RAND $19.17
- Resistance Level
- ATNM $1.48
- RAND $21.28
- Average True Range (ATR)
- ATNM 0.10
- RAND 0.88
- MACD
- ATNM 0.01
- RAND 0.23
- Stochastic Oscillator
- ATNM 75.00
- RAND 86.02
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.